These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 2622456)
1. Attack on neoplastic cell membranes by therapeutic antibody. Stevenson GT Mol Cell Biochem; 1989 Nov 23-Dec 19; 91(1-2):33-8. PubMed ID: 2622456 [TBL] [Abstract][Full Text] [Related]
2. A chimeric antibody with dual Fc regions (bisFabFc) prepared by manipulations at the IgG hinge. Stevenson GT; Pindar A; Slade CJ Anticancer Drug Des; 1989 Mar; 3(4):219-30. PubMed ID: 2930624 [TBL] [Abstract][Full Text] [Related]
3. Comparative efficiencies of bispecific F(ab'gamma)2 and chimeric mouse/human IgG antibodies in recruiting cellular effectors for cytotoxicity via Fc gamma receptors. Greenman J; Hogg N; Nikoletti S; Slade C; Stevenson G; Glennie M Cancer Immunol Immunother; 1992; 34(6):361-9. PubMed ID: 1532922 [TBL] [Abstract][Full Text] [Related]
4. Activation of complement pathways by univalent antibody derivatives with intact Fc zones. Watts HF; Anderson VA; Cole VM; Stevenson GT Mol Immunol; 1985 Jul; 22(7):803-10. PubMed ID: 3849671 [TBL] [Abstract][Full Text] [Related]
6. Thioether-bonded constructs of Fab'gamma and Fc gamma modules utilizing differential reduction of interchain disulfide bonds. Kan KS; Anderson VA; Leong WS; Smith AM; Worth AT; Stevenson GT J Immunol; 2001 Jan; 166(2):1320-6. PubMed ID: 11145716 [TBL] [Abstract][Full Text] [Related]
7. Characterization of a new monoclonal anti-Fc gamma RII antibody, AT10, and its incorporation into a bispecific F(ab')2 derivative for recruitment of cytotoxic effectors. Greenman J; Tutt AL; George AJ; Pulford KA; Stevenson GT; Glennie MJ Mol Immunol; 1991 Nov; 28(11):1243-54. PubMed ID: 1835758 [TBL] [Abstract][Full Text] [Related]
9. Conjugation of human Fc gamma in closed-hinge or open-hinge configuration to Fab'gamma and analogous ligands. Stevenson GT; Anderson VA; Kan KS; Worth AT J Immunol; 1997 Mar; 158(5):2242-50. PubMed ID: 9036971 [TBL] [Abstract][Full Text] [Related]
10. Preparation and properties of FabIgG, a chimeric univalent antibody designed to attack tumour cells. Stevenson GT; Glennie MJ; Paul FE; Stevenson FK; Watts HF; Wyeth P Biosci Rep; 1985; 5(10-11):991-8. PubMed ID: 3879458 [TBL] [Abstract][Full Text] [Related]
11. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells. Tutt A; Stevenson GT; Glennie MJ J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655 [TBL] [Abstract][Full Text] [Related]
12. Bispecific F (ab')2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells. Nitta T; Yagita H; Azuma T; Sato K; Okumura K Eur J Immunol; 1989 Aug; 19(8):1437-41. PubMed ID: 2528460 [TBL] [Abstract][Full Text] [Related]
13. Loss of surface-bound antibody accompanying the anti-complementary modulation of leukemic B cell immunoglobulin: contrasting effects of antibodies directed against idiotypic and constant regions. Gordon J; Anderson VA; Stevenson GT J Immunol; 1982 Jun; 128(6):2863-9. PubMed ID: 6804570 [TBL] [Abstract][Full Text] [Related]
14. Monoclonal anti-IgG autoantibodies derived from lipopolysaccharide-activated spleen cells of 129/Sv mice. Van Snick JL; Coulie P J Exp Med; 1982 Jan; 155(1):219-30. PubMed ID: 6976413 [TBL] [Abstract][Full Text] [Related]
15. Production of antibodies specific for Fc, Fab', and streptokinase-streptodornase in vitro by peripheral blood cells from patients with rheumatoid arthritis and normal donors. Identification of immune complexes in culture supernatants containing hidden antibodies reactive with Fab' fragments of immunoglobulin G. Birdsall HH; Rossen RD J Clin Invest; 1982 Jan; 69(1):75-84. PubMed ID: 6976356 [TBL] [Abstract][Full Text] [Related]
16. Antigenic modulation of lymphocytic surface immunoglobulin yielding resistance to complement-mediated lysis. II. Relationship to redistribution of the antigen. Gordon J; Stevenson GT Immunology; 1981 Jan; 42(1):13-7. PubMed ID: 6970171 [TBL] [Abstract][Full Text] [Related]
17. Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B-cells. Cragg MS; Zhang L; French RR; Glennie MJ Br J Cancer; 1999 Feb; 79(5-6):850-7. PubMed ID: 10070880 [TBL] [Abstract][Full Text] [Related]
18. The use of Fab-Fc recombinant antibodies for studying the mechanism of triggering the effector activities of immunoglobulins. Uracz W; Bobrzecka K; Konieczny L; Rybarska J; Zembala M Immunol Lett; 1984; 7(4):215-20. PubMed ID: 6706380 [TBL] [Abstract][Full Text] [Related]
19. Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59. Harris CL; Kan KS; Stevenson GT; Morgan BP Clin Exp Immunol; 1997 Feb; 107(2):364-71. PubMed ID: 9030877 [TBL] [Abstract][Full Text] [Related]
20. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32). Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]